 |
 |
||||||
 |
Feedback unseren Kunden |
Ihr Warenkorb
€0.00 (0 artikel)
| |||||
|
| ||||||||||||||||||
- Pill for chest pains ‘could save 10,000 lives a year’
A pill for chest pains that costs around £10 per week could save the lives of thousands of heart failure patients.
- Low-carb and low-fat diets equally good for weight loss
Both low-fat and low-carb diets work equally well to help people lose weight over two years, new research has shown.
- Hope and controversy over prostate cancer screening
Screening older men with the PSA blood test could cut prostate cancer deaths by around half, according to a new study.
- Antidepressant use rises as recession feeds wave of worry
The number of antidepressants prescribed by the NHS has almost doubled in the last decade, and rose sharply last year as the recession bit, figures reveal.
- Overtime could break your heart
Overtime is bad for the heart, according to researchers who followed the careers of more than 6,000 Whitehall civil servants.
Unsere Rechnungsführung ist zertifiziert durch:
- Side effects of Asacol - Helium
Side effects of AsacolHeliumby Dr Pandula Siribaddana Asacol can be described as an anti-inflammatory drug which contains the active ingredient mesalamine.
- FDA Gives Mixed Verdict on Generic Mesalamine Citizen Petitions - FDA news (subscription)
FDA Gives Mixed Verdict on Generic Mesalamine Citizen PetitionsFDA news (subscription).
- Salix Pharmaceuticals to Present at Stifel Nicolaus Conference - MarketWatch (press release)
MRO (press release)Salix Pharmaceuticals to Present at Stifel Nicolaus ConferenceMarketWatch (press release).
- WCRX: CP Raises Hurdle But Provides Little Clarity - Benzinga
WCRX: CP Raises Hurdle But Provides Little ClarityBenzingaThe FDA denied the request for formal bioequivalence guidelines for mesalamine generics.
- Warner Chilcott Announces Receipt of FDA Response to Citizen Petition - MarketWatch (press release)
Warner Chilcott Announces Receipt of FDA Response to Citizen PetitionMarketWatch (press release)In its petition, Warner Chilcott requested that the FDA (1) issue bioequivalence guidance for mesalamine delayed-release tablets, (2) not approve any .
|
| Copyright © www.indiapharmacyonline.com. All rights reserved. |